ODD is a modest positive catalyst — it lowers future development cost but does not change clinical probability of success. Phase 1 data updates in coming quarters will be the next price-relevant catalyst. The buy-side consensus is heavily bullish (95% strong buy/buy), suggesting limited incremental surprise from this news.
Price Chart
Executive Summary
Cullinan Therapeutics announced that the FDA granted Orphan Drug Designation (ODD) to its CLN-049, a FLT3xCD3 T cell engager, for relapsed/refractory acute myeloid leukemia (AML). ODD provides development incentives, including tax credits, fee exemptions, and potential seven-year U.S. market exclusivity upon approval, but is a procedural milestone with limited direct stock impact for a clinical-stage biotech.
Key Facts
- FDA granted Orphan Drug Designation to CLN-049 for relapsed/refractory AML
- ODD provides tax credits, FDA fee exemptions, and potential 7-year exclusivity
- CLN-049 is a novel FLT3xCD3 T cell engager targeting both mutated and non-mutated FLT3
- CLN-049 is in Phase 1 trials (NCT05143996, EUCT 2023-506572-27-00) and has Fast Track designation
- Approximately 22,000 new AML cases/year in the U.S.; 5-year survival in R/R is ~10% or less
Financial Impact
No financial figures disclosed. ODD reduces development costs via fee waivers and tax credits but provides no revenue or approval guarantee.
Risk Factors
- Phase 1 clinical development still ongoing; safety/efficacy failures remain the dominant risk
- AML competitive landscape includes approved targeted therapies (e.g., gilteritinib, midostaurin) and other bispecifics in development
- ODD does not guarantee accelerated approval or commercial success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297322 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | Press Release | $15.51 | awaiting T+60 | — | $14.54 (−6.25%) |
Sep 24, 2026 4w ago | 8-K | $15.44 | awaiting T+60 | — | $14.54 (−5.83%) |
Sep 24, 2026 4w ago | Press Release | $15.44 | awaiting T+60 | — | $14.54 (−5.83%) |
Sep 22, 2026 4w ago | Institutional Cluster | $21.67 | awaiting T+60 | — | $14.54 (−32.90%) |
Sep 14, 2026 6w ago | 8-K | $20.40 | awaiting T+60 | — | $14.54 (−28.73%) |
Aug 6, 2026 11w ago | 8-K | $17.95 | awaiting T+60 | — | $14.54 (−19.00%) |
Jun 11, 2026 19w ago | Institutional Cluster | $12.98 $21.69 | ▲ +67.10% | ▲ +63.28% | $14.54 (+12.02%) |
Jun 10, 2026 19w ago | Press Release | $12.05 $22.09 | ▲ +83.32% | ▲ +77.15% | $14.54 (+20.66%) |
Jun 8, 2026 20w ago | 8-K | $13.28 $22.33 | ▲ +68.15% | ▲ +64.64% | $14.54 (+9.49%) |
May 19, 2026 22w ago | Press Release | $14.18 $19.64 | ▲ +38.55% | ▲ +32.26% | $14.54 (+2.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers